Lyell Immunopharma, Inc. ( (LYEL) ) has released its Q3 earnings. Here is a breakdown of the information Lyell Immunopharma, Inc. presented to its investors.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Lyell Immunopharma, Inc. is a late-stage clinical cell therapy company focused on developing next-generation autologous chimeric antigen receptor (CAR) T-cell product candidates for hematologic malignancies and solid tumors. In its latest earnings report for the quarter ending September 30, 2025, Lyell Immunopharma highlighted a net loss of $38.8 million, a decrease from the previous year’s loss of $44.6 million for the same period. The company reported revenues of $15,000, a slight decline compared to $34,000 in the previous year. Key financial metrics showed total assets of $408 million, with cash and cash equivalents increasing to $123.6 million from $105.6 million at the end of 2024. The company also completed a PIPE financing, raising $57.8 million, and issued additional shares as part of contingent consideration related to its acquisition of ImmPACT Bio USA Inc. Looking ahead, Lyell Immunopharma is focused on advancing its lead product candidate, rondecabtagene autoleucel, and other pipeline projects, with management expressing confidence in their cash reserves to support operations for the foreseeable future.